期刊
ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA
卷 31, 期 1, 页码 23-28出版社
EDICIONES DOYMA S A
DOI: 10.1016/j.eimc.2012.03.003
关键词
Voriconazole; Therapeutic drug monitoring; High performance liquid chromatography; Ravuconazole
资金
- Fondo de Investigaciones Sanitarias (Health Research Fund) (FIS) [PI09/0624]
- Fondo de Investigaciones Sanitarias [CM08/0083]
- Astellas Pharma
- bioMerieux
- Gilead Sciences
- Merck Sharp
- Dohme
- Pfizer
- Schering Plough
- Soria Melguizo SA
- European Union
- ALBAN program
- Spanish Agency for International Cooperation
- Spanish Ministry of Culture and Education
- Spanish Health Research Fund
- Instituto de Salud Carlos III
- Ramon Areces Foundation
- Mutua Madrilena Foundation
The aim of this study was the development and validation of a fast and simple high performance liquid chromatography method for measuring voriconazole in human serum using ravuconazole as an external standard. The experience of the reference laboratory in therapeutic drug monitoring of voriconazole is also reported. This method is based on the precipitation of proteins in human serum and detection by HPLC/UV. Chromatographic separation is achieved using an isocratic solvent delivery with detection at 255 nm and a run time of 7 min. The assay was validated according to international guidelines and was also applied to the analysis of 141 trough serum samples from patients treated with voriconazole. All validation parameters met the criteria set out in FDA guidelines for bioanalytical methods. A high interpatient and intrapatient variability was observed in clinical samples. This method is accurate enough to perform therapeutic drug monitoring in patients receiving voriconazole treatment. (C) 2012 Elsevier Espana, S.L. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据